Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.20 | 5.20 | 0.06% |
| CAC 40 | 8,123.41 | 31.50 | -0.39% |
| DAX 40 | 25,426.79 | 152.06 | -0.59% |
| Dow JONES (US) | 51,545.53 | 318.16 | -0.61% |
| FTSE 100 | 10,705.26 | 3.07 | -0.03% |
| HKSE | 24,834.12 | 253.63 | -1.01% |
| NASDAQ | 26,964.88 | 279.40 | -1.03% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.76 | 53.72 | -0.39% |
| S&P 500 | 7,715.14 | 49.50 | -0.64% |
| S&P/ASX 200 | 8,765.30 | 7.50 | 0.09% |
| SSE Composite Index | 3,936.52 | 15.61 | -0.39% |